This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Genetics

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The fragile X syndrome increases in severity down the generations of an affected family. This is termed genetic anticipation.

The gene which is most commonly responsible is FMR-1 (familial mental retardation 1).

The expression of the FMR-1 gene (locus FRAXA) is disrupted by large numbers of trinuclotide (CGG) repeats. The number of repeats determines the phenotype:

  • normal - less than 50 CGG repeats
  • premutation - 50-230 repeats
  • mutation - hundreds of repeats

The premutation does not impair intelligence but is unstable. During oogenesis, but not during spermatogenesis, the premutation may expand to form the full mutation.

Of the patients carrying the full mutation:

  • 80% of males are mentally retarded
  • 20% of males are normal and are termed "transmitting males"
  • 30% of females are mildly mentally retarded (except if the gene is inherited from a transmitting male, in which case the daughter is unaffected but is an obligate carrier)

Two further loci for the fragile X syndrome have been discovered, both are caused by a CGG/CCG expansion:

  • FRAXE
  • FRAXF

Reference:

  • 1) Annemieke, JMH. et al. (1991). Cell. 65, 905-14.
  • 2) Knight, SJL. et al. (1993). Cell. 74, 127-134.
  • 3) Parrish, JE. et al. (1994). Nature Genet. 8, 236-242.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.